
Women are the predominant users of these drugs, and the authors say guidance has not kept pace, with nutrient gaps and supplement support also in focus.
The agency’s has weighed in on 536 new claims.
For three months, industry has awaited the European Food Safety Authority’s (EFSA) fifth batch of general function health claims. Now, the agency’s expert NDA Panel has weighed in on 536 new claims.
Here’s the NDA Panel’s opinion of its approved claims:
The majority of submitted ingredient claims, were unsuccessful including:
With the support of EFSA’s reviews, the European Commission and its member states can now decide on whether or not to authorize claims on products relating to these ingredients.
EFSA will publish reviews of 35 remaining claims in July.






